Spotlight On BPA: Science And Litigation

Law360, New York (September 20, 2012, 3:19 PM ET) -- Bisphenol A (BPA), one of the so-called endocrine disrupters,[1] has been the target of continued legislative and regulatory action, and the federal government has devoted tens of millions of dollars toward its study. This brief article summarizes events from the last few years, showing how, in my opinion, a useful product can be denigrated by poor science and virtually marginalized out of existence.

Legislative and Regulatory Activities

In October 2008, the Natural Resources Defense Council started the ball rolling by filing a citizen petition[2] requesting that...
To view the full article, take a free trial now.
Try Law360 for free for seven days
Already a subscriber? Click here to login

Already have access?

  1. Forgot your password?
  2. Sign In

Get instant access to the one-stop news source for business lawyers

Required